ONCO - חוב כולל להון Onconetix Corporation

This chart of the separate_debt_total_eq metric for Onconetix, Inc. (ONCO) stands at 0.01. The business focuses on developing oncology and men's health products, where patents drive profitability while maintaining low personnel costs. The operating model relies on third-party contractors for testing and drug synthesis, while the current strategy is limited solely to maintaining legacy licenses without new discoveries.

Selecting assets with a high margin of safety requires analyzing the share of borrowed funds within the capital structure, which allows for an assessment of the business's financial resilience to market shocks. Calculating the ratio of total liabilities to equity in the current leverage metric (total debt to equity) helps determine the extent to which the commercialization of unique oncological drugs by Onconetix, Inc. (ONCO) relies on leverage or internal resources.